Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention

European Journal of Cardio-thoracic Surgery

Volumn 35, Issue 3, 2009, Pages 493-504

  Parolari, Alessandro ^a   Loardi, Claudia ^a   Mussoni, Luciana ^b   Cavallotti, Laura ^a   Camera, Marina ^a,b   Biglioli, Paolo ^a   Tremoli, Elena ^a,b   Alamanni, Francesco ^a  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Calcific aortic valve stenosis; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CANDESARTAN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RGS2 PROTEIN; RGS4 PROTEIN; ROSUVASTATIN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; AORTA VALVE STENOSIS; ATHEROSCLEROSIS; BONE METABOLISM; CALCIFICATION; CLINICAL TRIAL; DRUG INDICATION; DRUG MEGADOSE; EXTRACELLULAR MATRIX; GENETIC RISK; HEMOSTASIS; HISTOPATHOLOGY; HUMAN; INFECTION; INFLAMMATION; LIPID METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

AGE FACTORS; AORTIC VALVE STENOSIS; BONE DENSITY; CALCINOSIS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; SEVERITY OF ILLNESS INDEX;

EID: 60849104778     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.11.033     Document Type: Review

References (141)

1. Moura L.M., Maganti K., Puthumana J.J., Rocha-Goncalves F., and Rajamannan N.M. New understanding about calcific aortic stenosis and opportunities for pharmacologic intervention. Curr Opin Cardiol 22 (2007) 572-577
2. Rajamannan N.M., and Otto C.M. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110 (2004) 1180-1182
3. Iung B., Baron G., Butchart E.G., Delahaye F., Gohlke-Barwolf C., Levang O.W., Tornos P., Vanoverschelde J.L., Vermeer F., Boersma E., Ravaud P., and Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24 (2003) 1231-1243
4. Rajamannan N.M. Calcific aortic stenosis: medical and surgical management in the elderly. Curr Treat Options Cardiovasc Med 7 (2005) 437-442
5. Otto C.M., Lind B.K., Kitzman D.W., Gersh B.J., and Siscovick D.S. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341 (1999) 142-147
6. Stewart B.F., Siscovick D., Lind B.K., Gardin J.M., Gottdiener J.S., Smith V.E., Kitzman D.W., Otto C.M., and Cardiovascular Health Study. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol 29 (1997) 630-634
7. Lindroos M., Kupari M., Heikkila J., and Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 21 (1993) 1220-1225
8. Wilmshurst P.T., Stevenson R.N., Griffiths H., and Lord J.R. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart 78 (1997) 475-479
9. Avakian S.D., Annicchino-Bizzacchi J.M., Grinberg M., Ramires J.A., and Mansura A.P. Apolipoproteins AI, B, and E polymorphisms in severe aortic valve stenosis. Clin Genet 60 (2001) 381-384
10. Ortlepp J.R., Pillich M., Mevissen V., Krantz C., Kimmel M., Autschbach R., Langebartels G., Erdmann J., Hoffmann R., and Zerres K. APOE alleles are not associated with calcific aortic stenosis. Heart 92 (2006) 1463-1466
11. Novaro G.M., Sachar R., Pearce G.L., Sprecher D.L., and Griffin B.P. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 108 (2003) 1804-1808
12. Ortlepp J.R., Schmitz F., Mevissen V., Weiss S., Huster J., Dronskowski R., Langebartels G., Autschbach R., Zerres K., Weber C., Hanrath P., and Hoffmann R. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 25 (2004) 514-522
13. Ortlepp J.R., Hoffmann R., Ohme F., Lauscher J., Bleckmann F., and Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 85 (2001) 635-638
14. Morrison N.A., Qi J.C., Tokita A., Kelly P.J., Crofts L., Nguyen T.V., Sambrook P.N., and Eisman J.A. Prediction of bone density from vitamin D receptor alleles. Nature 367 (1994) 284-287
15. Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R., King I.N., Grossfeld P.D., and Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature 437 (2005) 270-274
16. Nordstrom P., Glader C.A., Dahlen G., Birgander L.S., Lorentzon R., Waldenstrom A., and Lorentzon M. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med 254 (2003) 140-146
17. Golubnitschaja O., Yeghiazaryan K., Skowasch D., Schild H., and Bauriedel G. p21WAF1/CIP1 and 14-3-3 sigma gene expression in degenerated aortic valves: a link between cell cycle checkpoints and calcification. Amino Acids 31 (2006) 309-316
18. O'Brien K.D., Reichenbach D.D., Marcovina S.M., Kuusisto J., Alpers C.E., and Otto C.M. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16 (1996) 523-532
19. Rashidi A., Adler D.S., Casscells W., and Madjid M. Is it time to prescribe statins to patients with calcified aortic stenosis?. Am Heart J 150 (2005) 41-45
20. Helske S., Kupari M., Lindstedt K.A., and Kovanen P.T. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 18 (2007) 483-491
21. Poggianti E., Venneri L., Chubuchny V., Jambrik Z., Baroncini L.A., and Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol 41 (2003) 136-141
22. Baldassarre D., De Jong A., Amato M., Werba J.P., Castelnuovo S., Frigerio B., Veglia F., Tremoli E., and Sirtori C.R. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. Ann Med 40 (2008) 21-44
23. Yamaura Y., Nishida T., Watanabe N., Akasaka T., and Yoshida K. Relation of aortic valve sclerosis to carotid artery intima-media thickening in healthy subjects. Am J Cardiol 94 (2004) 837-839
24. Branch K.R., O'Brien K.D., and Otto C.M. Aortic valve sclerosis as a marker of active atherosclerosis. Curr Cardiol Rep 4 (2002) 111-117
25. Faggiano P., Antonini-Canterin F., Erlicher A., Romeo C., Cervesato E., Pavan D., Piazza R., Huang G., and Nicolosi G.L. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol 91 (2003) 99-101
26. Novaro G.M., and Griffin B.P. Calcific aortic stenosis: another face of atherosclerosis?. Cleve Clin J Med 70 (2003) 471-477
27. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., and O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 (1994) 844-853
28. Ghaisas N.K., Foley J.B., O'Briain D.S., Crean P., Kelleher D., and Walsh M. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 36 (2000) 2257-2262
29. Diehl P., Nagy F., Sossong V., Helbing T., Beyersdorf F., Olschewski M., Bode C., and Moser M. Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thromb Haemost 99 (2008) 711-719
30. Chalajour F., Treede H., Ebrahimnejad A., Lauke H., Reichenspurner H., and Ergun S. Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp Cell Res 298 (2004) 455-464
31. Helske S., Miettinen T., Gylling H., Mayranpaa M., Lommi J., Turto H., Werkkala K., Kupari M., and Kovanen P.T. Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves. J Lipid Res 49 (2008) 1511-1518
32. O'Brien K.D., Shavelle D.M., Caulfield M.T., McDonald T.O., Olin-Lewis K., Otto C.M., and Probstfield J.L. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106 (2002) 2224-2230
33. Caira F.C., Stock S.R., Gleason T.G., McGee E.C., Huang J., Bonow R.O., Spelsberg T.C., McCarthy P.M., Rahimtoola S.H., and Rajamannan N.M. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47 (2006) 1707-1712
34. Rajamannan N.M., Edwards W.D., and Spelsberg T.C. Hypercholesterolemic aortic-valve disease. N Engl J Med 349 (2003) 717-718
35. Palta S., Pai A.M., Gill K.S., and Pai R.G. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101 (2000) 2497-2502
36. Peltier M., Trojette F., Sarano M.E., Grigioni F., Slama M.A., and Tribouilloy C.M. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 91 (2003) 97-99
37. Gerber Y., Goldbourt U., Feinberg M.S., Segev S., and Harats D. Are triglyceride-rich lipoproteins associated with aortic valve sclerosis? A preliminary report. Atherosclerosis 170 (2003) 301-305
38. Owens D.S., Katz R., Johnson E., Shavelle D.M., Probstfield J.L., Takasu J., Crouse J.R., Carr J.J., Kronmal R., Budoff M.J., and O'Brien K.D. Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Arch Intern Med 168 (2008) 1200-1207
39. Briand M., Lemieux I., Dumesnil J.G., Mathieu P., Cartier A., Despres J.P., Arsenault M., Couet J., and Pibarot P. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 47 (2006) 2229-2236
40. Pohle K., Maffert R., Ropers D., Moshage W., Stilianakis N., Daniel W.G., and Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104 (2001) 1927-1932
41. Yilmaz M.B., Guray U., Guray Y., Cihan G., Caldir V., Cay S., Kisacik H.L., and Korkmaz S. Lipid profile of patients with aortic stenosis might be predictive of rate of progression. Am Heart J 147 (2004) 915-918
42. Mohty D., Pibarot P., Despres J.P., Cote C., Arsenault B., Cartier A., Cosnay P., Couture C., and Mathieu P. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28 (2008) 187-193
43. Cote C., Pibarot P., Despres J.P., Mohty D., Cartier A., Arsenault B.J., Couture C., and Mathieu P. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 94 (2008) 1175-1180
44. Busseuil D., Shi Y., Mecteau M., Brand G., Kernaleguen A.E., Thorin E., Latour J.G., Rheaume E., and Tardif J.C. Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol 154 (2008) 765-773
45. Helske S., Oksjoki R., Lindstedt K.A., Lommi J., Turto H., Werkkala K., Kupari M., and Kovanen P.T. Complement system is activated in stenotic aortic valves. Atherosclerosis 196 (2008) 190-200
46. Kaden J.J., Dempfle C.E., Grobholz R., Tran H.T., Kilic R., Sarikoc A., Brueckmann M., Vahl C., Hagl S., Haase K.K., and Borggrefe M. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 170 (2003) 205-211
47. Anger T., Pohle F.K., Kandler L., Barthel T., Ensminger S.M., Fischlein T., Weyand M., Stumpf C., Daniel W.G., and Garlichs C.D. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins. Exp Mol Pathol 83 (2007) 435-442
48. Jian B., Narula N., Li Q.Y., Mohler III E.R., and Levy R.J. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75 (2003) 457-465 [discussion 65-6]
49. Kaden J.J., Dempfle C.E., Grobholz R., Fischer C.S., Vocke D.C., Kilic R., Sarikoc A., Pinol R., Hagl S., Lang S., Brueckmann M., and Borggrefe M. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 14 (2005) 80-87
50. Mazzone A., Epistolato M.C., Gianetti J., Castagnini M., Sassi C., Ceravolo R., Bevilacqua S., Glauber M., Biagini A., and Tanganelli P. Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease?. Am J Clin Pathol 126 (2006) 494-502
51. Mazzone A., Epistolato M.C., De Caterina R., Storti S., Vittorini S., Sbrana S., Gianetti J., Bevilacqua S., Glauber M., Biagini A., and Tanganelli P. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 43 (2004) 1670-1676
52. Meng X., Ao L., Song Y., Babu A., Yang X., Wang M., Weyant M.J., Dinarello C.A., Cleveland Jr. J.C., and Fullerton D.A. Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol 294 (2008) C29-35
53. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K., Sarikoc A., Kilic R., Brueckmann M., Lang S., Zahn I., Vahl C., Hagl S., Dempfle C.E., and Borggrefe M. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36 (2004) 57-66
54. Steinmetz M., Skowasch D., Wernert N., Welsch U., Preusse C.J., Welz A., Nickenig G., and Bauriedel G. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis 17 (2008) 187-193
55. Morishima A., Marui A., Shimamoto T., Saji Y., Tambara K., Nishina T., and Komeda M. Successful aortic valve replacement for Heyde syndrome with confirmed hematologic recovery. Ann Thorac Surg 83 (2007) 287-288
56. Pareti F.I., Lattuada A., Bressi C., Zanobini M., Sala A., Steffan A., and Ruggeri Z.M. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 102 (2000) 1290-1295
57. Vincentelli A., Susen S., Le Tourneau T., Six I., Fabre O., Juthier F., Bauters A., Decoene C., Goudemand J., Prat A., and Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349 (2003) 343-349
58. Yoshida K., Tobe S., and Kawata M. Acquired von Willebrand disease type IIA in patients with aortic valve stenosis. Ann Thorac Surg 81 (2006) 1114-1116
59. Yoshida K., Tobe S., Kawata M., and Yamaguchi M. Acquired and reversible von Willebrand disease with high shear stress aortic valve stenosis. Ann Thorac Surg 81 (2006) 490-494
60. Olsson M., Hultcrantz R., Schulman S., and Wallgren E. Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome-normalization of bleeding time after aortic valve replacement. J Intern Med 252 (2002) 516-523
61. Goldsmith I.R., Blann A.D., Patel R.L., and Lip G.Y. Effect of aortic valve replacement on plasma soluble P-selectin, von Willebrand factor, and fibrinogen. Am J Cardiol 87 (2001) 107-L110 A9
62. Moriyama Y., Nakamura K., Kariyazono H., Toyohira H., and Taira A. Influence of low-intensity anticoagulation and low-dose antiplatelet agent on coagulation-fibrinolysis system after mechanical prosthetic valve replacement. J Thorac Cardiovasc Surg 115 (1998) 952-954
63. Iida M., Yamamoto M., Yamazaki M., Sawaguchi M., Honjo H., Kodama I., and Kamiya K. Association of aortic valve sclerosis with thrombin generation in hypertensive patients. J Hum Hypertens 22 (2008) 781-787
64. Marechaux S., Corseaux D., Vincentelli A., Richardson M., Ung A., Susen S., Zawadzki C., Beregi J.P., Ezekowitz M.D., Jude B., and Le Tourneau T. Identification of tissue factor in experimental aortic valve sclerosis. Cardiovasc Pathol (2008) 10.1016/j.carpath.2007.12.014
65. Risau W. Angiogenesis and endothelial cell function. Arzneimittelforschung 44 (1994) 416-417
66. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
67. Chen F., Eriksson P., Kimura T., Herzfeld I., and Valen G. Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque. Coron Artery Dis 16 (2005) 191-197
68. Mofidi R., Crotty T.B., McCarthy P., Sheehan S.J., Mehigan D., and Keaveny T.V. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 88 (2001) 945-950
69. Soini Y., Salo T., and Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol 34 (2003) 756-763
70. Charest A., Pepin A., Shetty R., Cote C., Voisine P., Dagenais F., Pibarot P., and Mathieu P. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 92 (2006) 1844-1849
71. Sage E.H. Regulation of interactions between cells and extracellular matrix: a command performance on several stages. J Clin Invest 107 (2001) 781-783
72. Chalajour F., Treede H., Gehling U.M., Ebrahimnejad A., Boehm D.H., Riemer R.K., Ergun S., and Reichenspurner H. Identification and characterization of cells with high angiogenic potential and transitional phenotype in calcific aortic valve. Exp Cell Res 313 (2007) 2326-2335
73. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
74. Edep M.E., Shirani J., Wolf P., and Brown D.L. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 9 (2000) 281-286
75. Fondard O., Detaint D., Iung B., Choqueux C., Adle-Biassette H., Jarraya M., Hvass U., Couetil J.P., Henin D., Michel J.B., Vahanian A., and Jacob M.P. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 26 (2005) 1333-1341
76. Kaden J.J., Vocke D.C., Fischer C.S., Grobholz R., Brueckmann M., Vahl C.F., Hagl S., Haase K.K., Dempfle C.E., and Borggrefe M. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. Z Kardiol 93 (2004) 124-130
77. Satta J., Oiva J., Salo T., Eriksen H., Ohtonen P., Biancari F., Juvonen T.S., and Soini Y. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg 76 (2003) 681-688 [discussion 8]
78. Soini Y., Satta J., Maatta M., and Autio-Harmainen H. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol 194 (2001) 225-231
79. Jian B., Jones P.L., Li Q., Mohler III E.R., Schoen F.J., and Levy R.J. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 159 (2001) 321-327
80. Yeghiazaryan K., Skowasch D., Bauriedel G., Schild H., and Golubnitschaja O. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement. Amino Acids 32 (2007) 109-114
81. Helske S., Syvaranta S., Kupari M., Lappalainen J., Laine M., Lommi J., Turto H., Mayranpaa M., Werkkala K., Kovanen P.T., and Lindstedt K.A. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 27 (2006) 1495-1504
82. Helske S., Syvaranta S., Lindstedt K.A., Lappalainen J., Oorni K., Mayranpaa M.I., Lommi J., Turto H., Werkkala K., Kupari M., and Kovanen P.T. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol 26 (2006) 1791-1798
83. Kaden J.J. Towards medical therapy of calcific aortic stenosis lessons from molecular biology. Eur Heart J 28 (2007) 1795-1796
84. Mayranpaa M.I., Heikkila H.M., Lindstedt K.A., Walls A.F., and Kovanen P.T. Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion. Coron Artery Dis 17 (2006) 611-621
85. Miller J.D., Chu Y., Brooks R.M., Richenbacher W.E., Pena-Silva R., and Heistad D.D. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 52 (2008) 843-850
86. Liberman M., Bassi E., Martinatti M.K., Lario F.C., Wosniak Jr. J., Pomerantzeff P.M., and Laurindo F.R. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 28 (2008) 463-470
87. Haurani M.J., and Pagano P.J. Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: bellwether for vascular disease?. Cardiovasc Res 75 (2007) 679-689
88. Watson C., and Alp N.J. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci (Lond) 114 (2008) 509-531
89. Ieven M.M., and Hoymans V.Y. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Microbiol 43 (2005) 19-24
90. Porqueddu M., Spirito R., Parolari A., Zanobini M., Pompilio G., Polvani G., Alamanni F., Stangalini D., Tremoli E., and Biglioli P. Lack of association between serum immunoreactivity and Chlamydia pneumoniae detection in the human aortic wall. Circulation 106 (2002) 2647-2648
91. Agmon Y., Khandheria B.K., Jamil Tajik A., Seward J.B., Sicks J.D., Fought A.J., O'Fallon W.M., Smith T.F., Wiebers D.O., and Meissner I. Inflammation, infection, and aortic valve sclerosis; Insights from the Olmsted County (Minnesota) population. Atherosclerosis 174 (2004) 337-342
92. Atar S., Tolstrup K., Cercek B., and Siegel R.J. Chlamydia pneumoniae antibody titers and cardiac calcifications: a cross-sectional serological-echocardiographic correlative study. Isr Med Assoc J 9 (2007) 517-520
93. Kaden J.J., Bickelhaupt S., Grobholz R., Brueckmann M., Haase K.K., Dempfle C.E., and Borggrefe M. Pathogenetic role of Chlamydia pneumoniae in calcific aortic stenosis: immunohistochemistry study and review of the literature. J Heart Valve Dis 12 (2003) 447-453
94. Radke P.W., Ortlepp J.R., Merkelbach-Bruse S., Kaiser A., Kronenberger S., Handt S., and Hanrath P. Prevalence of Chlamydia pneumoniae in nonrheumatic stenotic aortic valves. Am Heart J. 144 (2002) E12
95. Juvonen J., Juvonen T., Laurila A., Kuusisto J., Alarakkola E., Sarkioja T., Bodian C.A., Kairaluoma M.I., and Saikku P. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection?. Ann Intern Med 128 (1998) 741-744
96. Rose A.G. Failure to detect Chlamydia pneumoniae in senile calcific aortic stenosis or calcified congenital bicuspid aortic valve by immunofluorescence, polymerase chain reaction and electron microscopy. Cardiovasc Pathol 11 (2002) 300-304
97. Bratos-Perez M.A., Sanchez P.L., Garcia de Cruz S., Villacorta E., Palacios I.F., Fernandez-Fernandez J.M., Di Stefano S., Orduna-Domingo A., Carrascal Y., Mota P., Martin-Luengo C., Bermejo J., San Roman J.A., Rodriguez-Torres A., and Fernandez-Aviles F. Association between self-replicating calcifying nanoparticles and aortic stenosis: a possible link to valve calcification. Eur Heart J 29 (2008) 371-376
98. Maher E.R., Young G., Smyth-Walsh B., Pugh S., and Curtis J.R. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2 (1987) 875-877
99. McFalls E.O., and Archer S.L. Rapid progression of aortic stenosis and secondary hyperparathyroidism. Am Heart J 120 (1990) 206-208
100. Lindroos M., Kupari M., Valvanne J., Strandberg T., Heikkila J., and Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 15 (1994) 865-870
101. Ortlepp J.R., Pillich M., Schmitz F., Mevissen V., Koos R., Weiss S., Stork L., Dronskowski R., Langebartels G., Autschbach R., Brandenburg V., Woodruff S., Kaden J.J., and Hoffmann R. Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic stenosis. J Heart Valve Dis 15 (2006) 502-508
102. Linhartova K., Veselka J., Sterbakova G., Racek J., Topolcan O., and Cerbak R. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J 72 (2008) 245-250
103. Mohler III E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., and Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 103 (2001) 1522-1528
104. Rajamannan N.M., Subramaniam M., Rickard D., Stock S.R., Donovan J., Springett M., Orszulak T., Fullerton D.A., Tajik A.J., Bonow R.O., and Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 (2003) 2181-2184
105. Pohjolainen V., Taskinen P., Soini Y., Rysa J., Ilves M., Juvonen T., Ruskoaho H., Leskinen H., and Satta J. Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Hum Pathol 39 (2008) 1695-1701
106. Rajamannan N.M., Nealis T.B., Subramaniam M., Pandya S., Stock S.R., Ignatiev C.I., Sebo T.J., Rosengart T.K., Edwards W.D., McCarthy P.M., Bonow R.O., and Spelsberg T.C. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 111 (2005) 3296-3301
107. Babu A.N., Meng X., Zou N., Yang X., Wang M., Song Y., Cleveland J.C., Weyant M., Banerjee A., and Fullerton D.A. Lipopolysaccharide stimulation of human aortic valve interstitial cells activates inflammation and osteogenesis. Ann Thorac Surg 86 (2008) 71-76
108. Mallat Z., and Tedgui A. Unbalanced RANKL/RANK pathway in aortic valve sclerosis. J Mol Cell Cardiol 36 (2004) 17-19
109. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Assoc 292 (2004) 490-495
110. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev Genet 4 (2003) 638-649
111. Osman L., Chester A.H., Sarathchandra P., Latif N., Meng W., Taylor P.M., and Yacoub M.H. A novel role of the sympatho-adrenergic system in regulating valve calcification. Circulation 116 (2007) I282-I287
112. Osman L., Chester A.H., Amrani M., Yacoub M.H., and Smolenski R.T. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. Circulation 114 (2006) I566-I572
113. Verrier E.D., and Boyle Jr. E.M. Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg 62 (1996) 915-922
114. Chatzizisis Y.S., Coskun A.U., Jonas M., Edelman E.R., Feldman C.L., and Stone P.H. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 49 (2007) 2379-2393
115. Ridger V., Krams R., Carpi A., and Evans P.C. Hemodynamic parameters regulating vascular inflammation and atherosclerosis: a brief update. Biomed Pharmacother 62 (2008) 536-540
116. Helderman F., Segers D., de Crom R., Hierck B.P., Poelmann R.E., Evans P.C., and Krams R. Effect of shear stress on vascular inflammation and plaque development. Curr Opin Lipidol 18 (2007) 527-533
117. Harrison D.G., Widder J., Grumbach I., Chen W., Weber M., and Searles C. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 259 (2006) 351-363
118. Partridge J., Carlsen H., Enesa K., Chaudhury H., Zakkar M., Luong L., Kinderlerer A., Johns M., Blomhoff R., Mason J.C., Haskard D.O., and Evans P.C. Laminar shear stress acts as a switch to regulate divergent functions of NF-kappaB in endothelial cells. FASEB J 21 (2007) 3553-3561
119. Hastings N.E., Simmers M.B., McDonald O.G., Wamhoff B.R., and Blackman B.R. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol 293 (2007) C1824-C1833
120. Gelosa P., Cimino M., Pignieri A., Tremoli E., Guerrini U., and Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 3 (2007) 567-577
121. Werba J.P., Tremoli E., Massironi P., Camera M., Cannata A., Alamanni F., Biglioli P., and Parolari A. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg 76 (2003) 2132-2140
122. Liebe V., Brueckmann M., Borggrefe M., and Kaden J.J. Statin therapy of calcific aortic stenosis: hype or hope?. Eur Heart J 27 (2006) 773-778
123. Rajamannan N.M., Subramaniam M., Caira F., Stock S.R., and Spelsberg T.C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112 (2005) I229-I234
124. Rajamannan N.M., Subramaniam M., Stock S.R., Stone N.J., Springett M., Ignatiev K.I., McConnell J.P., Singh R.J., Bonow R.O., and Spelsberg T.C. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 91 (2005) 806-810
125. Wu B., Elmariah S., Kaplan F.S., Cheng G., and Mohler III E.R. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 25 (2005) 592-597
126. Anger T., El-Chafchak J., Habib A., Stumpf C., Weyand M., Daniel W.G., Hombach V., Hoeher M., and Garlichs C.D. Statins stimulate RGS-regulated ERK 1/2 activation in human calcified and stenotic aortic valves. Exp Mol Pathol 85 (2008) 101-111
127. Cowell S.J., Newby D.E., Prescott R.J., Bloomfield P., Reid J., Northridge D.B., and Boon N.A. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
128. Moura L.M., Ramos S.F., Zamorano J.L., Barros I.M., Azevedo L.F., Rocha-Goncalves F., and Rajamannan N.M. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007) 554-561
129. Rossebo A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., Gerdts E., Gohlke-Barwolf C., Holme I., Kesaniemi Y.A., Malbecq W., Nienaber C.A., Ray S., Skjaerpe T., Wachtell K., and Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008) 1343-1356
130. Peto R., Emberson J., Landray M., Baigent C., Collins R., Clare R., and Califf R. Analyses of cancer data from three ezetimibe trials. N Engl J Med 359 (2008) 1357-1366
131. Chan K.L., Teo K., Tam J., and Dumesnil J.G. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 153 (2007) 925-931
132. Novaro G.M., Tiong I.Y., Pearce G.L., Lauer M.S., Sprecher D.L., and Griffin B.P. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2205-2209
133. Aronow W.S., Ahn C., Kronzon I., and Goldman M.E. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88 (2001) 693-695
134. Bellamy M.F., Pellikka P.A., Klarich K.W., Tajik A.J., and Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 40 (2002) 1723-1730
135. Rosenhek R., Rader F., Loho N., Gabriel H., Heger M., Klaar U., Schemper M., Binder T., Maurer G., and Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
136. Shavelle D.M., Takasu J., Budoff M.J., Mao S., Zhao X.Q., and O'Brien K.D. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359 (2002) 1125-1126
137. O'Brien K.D., Zhao X.Q., Shavelle D.M., Caulfield M.T., Letterer R.A., Kapadia S.R., Probstfield J.L., and Otto C.M. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med 52 (2004) 185-191
138. Antonini-Canterin F., Hirsu M., Popescu B.A., Leiballi E., Piazza R., Pavan D., Ginghina C., and Nicolosi G.L. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 102 (2008) 738-742
139. Antonini-Canterin F., Corrado G., Faggiano P., Popescu B.A., Carerj S., La Carrubba S., Zuppiroli A., and Nicolosi G.L. A medical therapy for aortic valve sclerosis and aortic valve stenosis? Rationale of the ASSIST study (Asymptomatic aortic Sclerosis/Stenosis: Influence of STatins): a large, observational, prospective, multicenter study of the Italian Society of Cardiovascular Echography. J Cardiovasc Med (Hagerstown) 7 (2006) 464-469
140. Helske S., Lindstedt K.A., Laine M., Mayranpaa M., Werkkala K., Lommi J., Turto H., Kupari M., and Kovanen P.T. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44 (2004) 1859-1866
141. Arishiro K., Hoshiga M., Negoro N., Jin D., Takai S., Miyazaki M., Ishihara T., and Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 49 (2007) 1482-1489